Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
31,306,673
-
Total 13F shares
-
17,461,169
-
Share change
-
-341,661
-
Total reported value
-
$31,603,874
-
Price per share
-
$1.81
-
Number of holders
-
45
-
Value change
-
-$171,329
-
Number of buys
-
14
-
Number of sells
-
30
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) as of Q3 2025
As of 30 Sep 2025,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,461,169 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Sands Capital Alternatives, LLC, CITADEL ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, UBS Group AG, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, ACORN CAPITAL ADVISORS, LLC, BlackRock, Inc., and TWO SIGMA INVESTMENTS, LP.
This page lists
45
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.